drugset / Trial / NCT03216486

An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

NCT03216486

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the effect of BPS804 on strength/quality of bone in patients with Type I, III or IV Osteogenesis imperfecta using a special type of CT scanner. Participants will be treated for 1 year.

Timeline

Start
2017-10-31
Primary completion
2018-11-01
Completion
2018-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Setrusumab Monoclonal antibody Intravenous